LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.59 -3.64

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.56

Максимум

1.6

Ключови измерители
By Trading Economics
Приходи	13M -43M
Марж на печалбата	-2,190.837
Служители	171
EBITDA	17M -42M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+68.55% upside

Дивиденти
By Dow Jones
Следващи печалби	6.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.8M 106M
Предишно отваряне	5.23
Предишно затваряне	1.59

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.09.2025 г., 22:41 ч. UTC

Значими двигатели на пазара

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12.09.2025 г., 16:04 ч. UTC

Значими двигатели на пазара

Upexi Shares Climb on Solana Gains

12.09.2025 г., 15:03 ч. UTC

Значими двигатели на пазара

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

13.09.2025 г., 08:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

12.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

12.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.09.2025 г., 20:09 ч. UTC

Печалби

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12.09.2025 г., 19:23 ч. UTC

Пазарно говорене

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12.09.2025 г., 19:16 ч. UTC

Пазарно говорене

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12.09.2025 г., 19:03 ч. UTC

Пазарно говорене

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12.09.2025 г., 18:59 ч. UTC

Пазарно говорене

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12.09.2025 г., 18:38 ч. UTC

Пазарно говорене

Печалби

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12.09.2025 г., 18:33 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12.09.2025 г., 18:22 ч. UTC

Пазарно говорене

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12.09.2025 г., 16:56 ч. UTC

Пазарно говорене

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12.09.2025 г., 16:22 ч. UTC

Печалби

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.09.2025 г., 16:19 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12.09.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

12.09.2025 г., 16:11 ч. UTC

Печалби

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12.09.2025 г., 15:37 ч. UTC

Пазарно говорене

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12.09.2025 г., 15:22 ч. UTC

Пазарно говорене

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12.09.2025 г., 15:07 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12.09.2025 г., 14:34 ч. UTC

Пазарно говорене

Russia Sanctions Put Bid Back in Oil -- Market Talk

12.09.2025 г., 14:10 ч. UTC

Пазарно говорене

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12.09.2025 г., 13:58 ч. UTC

Пазарно говорене

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12.09.2025 г., 13:58 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12.09.2025 г., 13:57 ч. UTC

Печалби

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12.09.2025 г., 13:56 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

12.09.2025 г., 13:56 ч. UTC

Пазарно говорене

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

68.55% нагоре

12-месечна прогноза

Среден 2.68 USD 68.55%

Висок 4 USD

Нисък 1.7 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.